

BHP Supports Patient Care Through Medical Supplies Donation to PMH



Management from BHP and Princess Marina Hospital during the official handover of medical supplies.

The Botswana Harvard Health Partnership (BHP) reaffirmed its commitment to supporting its partners through the donation of essential medical supplies to Princess Marina Hospital (PMH), aimed at enhancing patient care and aiding frontline health workers.

On Thursday, 12 March 2026, BHP donated 1,800 units of intravenous (IV) fluids to the hospital. The consignment consisted of 600 units of Normal Saline (200 ml), 600 units of Ringer's Lactate (1,000 ml), and 600 units of Half-Strength Darrow's with 5% Glucose (200 ml), all critical for patient hydration, resuscitation, and overall clinical management.

In a continued show of support, BHP

handed over an additional 500 units of Injectable Ceftriaxone Sodium (antibiotic) BP 250 mg on Thursday, 19 March 2026. Ceftriaxone is a broad-spectrum antibiotic widely used in hospital settings to treat serious bacterial infections, making it an essential component of patient care.

The donation comes at a time when healthcare facilities continue to face increasing demand for essential supplies. By providing these critical resources, BHP is helping to ensure uninterrupted delivery of quality care to patients.

Speaking during the handover, BHP leadership emphasized the importance of strong partnerships

in addressing healthcare challenges. They noted that collaboration between institutions remains key to improving service delivery and achieving better health outcomes for communities across the country.

The first consignment was handed over by Director of Business Development and Sponsored Awards, Cornelius Gaetsaloe, and Operations Director, Dineo Thebe, alongside Procurement Manager Kabelo Matsagopane, Pharmacy Manager Tshepho Frank-Klass, and Communications Officer Topo Mosinyi. The BHP Executive Director officiated the second handover, reaffirming the organisation's ongoing support to PMH, where BHP is also based.

Receiving the donation, Hospital Superintendent Dr Tshepo Machacha expressed appreciation for the timely intervention, noting that the supplies would prove significant in supporting patient care. Clinical Director Dr Mosimanegape Nkwane highlighted the vital role of IV fluids in stabilizing patients and the importance of antibiotics such as ceftriaxone in managing infections.

Also present during the handover were PMH Public Relations Officer Keemenao Sampisi, Matron Cheneso Siku, and Deputy Matron Tumisang Lesetedi.

The initiative underscores BHP's broader mission of supporting national health priorities through collaboration, capacity building, and targeted interventions that directly benefit patients and healthcare providers.



Dr Tshepo Machacha, Princess Marina Hospital Superintendent

HVTN Assesses BHP as Potential Site for HVTN 808 Study



BHP team posing for a group photo with the HVTN delegation.

The Botswana Harvard Health Partnership (BHP) hosted a delegation from the HIV Vaccine Trials Network (HVTN) for a site assessment visit as part of its international site selection process for new protocols in the HVTN pipeline. These studies include the upcoming HVTN 808 one of the studies in the HVTN broadly neutralizing antibody series. The visit, which

took place from 18–19 March 2026, marked a key step in evaluating BHP's readiness to conduct this complex clinical trial.

The HVTN 808 study is "A nonrandomized phase 1 clinical trial to evaluate the safety and tolerability of an RNA HIV vaccine and RNA HIV vaccine boost immunogen

in combination with antiretroviral analytical treatment interruption (ATI) in people living with HIV, hypothesized to elicit vaccine-primed B cells, which produce broadly neutralizing HIV antibodies (bnAbs)”

To assess vaccine associated response, sampling in various body tissues and compartments shall be undertaken in lymph nodes and bone marrow. While another procedure to be undertaken shall be leukapheresis to analyse and measure the rare precursor B-cell populations that induce the production of desired bnAbs.

Since vaccination alone may not be sufficient to fully prime the antibodies, Analytical Treatment Interruption (ATI) is hypothesized to facilitate the participant’s own HIV at very low levels acting as a “natural booster” in the ultimate production of bnAbs capable of controlling the HIV virus.

If selected, BHP will conduct the study in collaboration with Sidilega Private Hospital, leveraging their capabilities to support the trial through the performance of the listed procedures.

The HVTN delegation comprised Michelle Nebergall, Clinical Trial Manager; Kagisho Baepanye, Community Education; Shanthie Pillay, Laboratory Operations; and Bongji Mabilane, Regional Medical Liaison, while Katekani Bayoli-Oseh joined virtually representing Pharmacy Operations.

On 18 March, Mr. Baepanye visited the Nkaikela Youth Group (NYG) and the Center for Youth of Hope (CEYOHO) to better understand how BHP collaborates with community stakeholders and to appreciate the critical role these organisations play in supporting research efforts. He also met with the BHP Community Advisory Board (CAB) to learn more about their engagement model and to present the proposed study.

Furthermore, on 18 March, the HVTN team met with the Sidilega Private Hospital team to present the study and tour the hospital’s haematology unit and laboratory facilities, key components for the successful implementation of the trial.

On 19 March, the delegation convened with key BHP units that would be involved in the study implementation were BHP to be selected as a site , including representatives from the clinic, laboratory, pharmacy, community engagement, data management, regulatory, and grants. During this session, the BHP HVTN team provided a comprehensive overview of

their state of readiness to undertake the study.

The meeting was followed by a Clinical Research Site (CRS) tour and appreciation of the BHP designated study space and assesment of critical operational areas, including Research Operations and Facilities (BHP Administration and Grants), Pharmacy Operations, Clinical Safety, Community Engagement, Laboratory Operations, and overall research infrastructure.

The site assessment enabled the HVTN team to evaluate BHP’s infrastructure, technical capacity, and community engagement framework, key considerations in selecting sites capable of conducting complex HIV vaccine trials.

The potential inclusion of HVTN 808 at BHP represents a significant opportunity to advance Botswana’s contribution to cutting-edge HIV research while reinforcing the importance of integrated, community-centered clinical trial implementation.



Prof Makhema with HVTN’s Michelle Nebergall, Bongji Mabilane and Shanthie Pillay.



HVTN’s Kagisho Baepanye addressing CEYOHO staff.

BHP Sets Strategic Direction for 2026 at Annual Plenary Meeting



BHP Executive Management, Departmental Heads, Study Coordinators and Principal Investigators at the plenary meeting.

The Botswana Harvard Health Partnership (BHP) convened its annual Study Coordinators Plenary Meeting on 6 March 2026, bringing together research teams, support services departments, and Executive Management to align on priorities for the year ahead.

The plenary served as a strategic platform for Study Coordinators and departmental representatives to present their 2026 plans, outlining key objectives, operational priorities, and focus areas across the organisation. It also provided an opportunity to reflect on achievements and challenges from the past year, while fostering alignment and shared direction for 2026.

Study Coordinators shared updates on ongoing and upcoming research projects, highlighting the breadth of BHP's portfolio across all its areas of research. Presentations also detailed plans to enhance participant engagement, improve data quality, and ensure timely and efficient study implementation.

Support services departments outlined their operational priorities for the year. These focused on strengthening internal systems, enhancing service delivery, and providing more effective support to research teams.

A key feature of the plenary was the interactive question-and-answer sessions following each presentation. These discussions facilitated open dialogue, enabling staff across different functions to seek clarity, share insights, and contribute to collective problem-solving.

Executive Management's presentations set the tone for the year by outlining BHP's overarching strategic priorities. Leadership emphasized scientific excellence, operational efficiency, and the sustained impact of BHP's work in HIV and broader public health research. They also underscored the importance of collaboration and coordination across departments to strengthen BHP's position as a regional leader in health research and capacity building.

The meeting reinforced was important as it encourages transparency, accountability, and integrated planning among BHP departments. By bringing together diverse teams on a single platform, the plenary strengthened organisational cohesion and alignment toward shared goals. The insights from the plenary are expected to guide the coordinated implementation of BHP research and operational agenda, supporting continued excellence and impact of its research.

BHP Participates at ORBIT Implementation Science Symposium



BHP team attending the ORBIT Implementation Science Symposium.

Botswana Harvard Health Partnership (BHP) joined national and international partners at the inaugural ORBIT Implementation Science Symposium, an event focused on strengthening evidence-based healthcare delivery in Botswana. The symposium, hosted on 4 March 2026 at Cresta Lodge, was organized by Botswana University of Maryland Health Initiative (BUMMHI) in collaboration with the Ministry of Health Botswana, University of Botswana, University of Maryland Baltimore, and BHP. The event forms part of the Optimize and Radiate Botswana Implementation Science and Training (ORBIT) project.

Held under the theme “From Evidence to Enduring Impact in Botswana: Advancing Country-led Implementation Science for Sustainable HIV and Health System Outcomes,” the symposium brought together policymakers, implementers, researchers, and key stakeholders from across the country.

The national forum provided a platform to share preliminary findings from ongoing implementation science studies in Botswana, with a strong focus on translating research evidence into practical, scalable interventions that can strengthen health systems and improve long-term HIV and public health outcomes.

Among the key contributions from BHP was a presentation by Dr Karen Shambira, who shared insights on the Tshireletso Study. The study evaluates the use of

long-acting injectable HIV prevention (CAB-LA) among postpartum and breastfeeding women, focusing on its safety, uptake, and feasibility within routine maternal care services.

BHP researchers’ participation underscored the institute’s commitment to advancing locally driven research that informs both policy and practice, particularly in critical areas such as HIV prevention, treatment, and health systems strengthening.

The symposium also emphasized the importance of collaboration between research institutions, government, and implementing partners to ensure that scientific findings are translated into sustainable, real-world impact.

Delivering the closing remarks, BHP Research Associate Professor Joseph Makhama called for continued collaboration among stakeholders, emphasizing that sustained partnerships are key to ensuring that implementation science translates into meaningful and lasting improvements in Botswana’s health system.

The ORBIT Implementation Science Symposium marks an important step in strengthening Botswana’s implementation science ecosystem, reinforcing partnerships, and accelerating progress toward achieving sustainable health outcomes.

BHP Takes Health Services to Sepako



Dr Kesegofetse Chabaesele, Medical Residents and partners posing for a group photo with the village leadership and the area Member of Parliament and Assistant Minister of Health, Lawrence Ookeditse.

From 19–21 March 2026, Botswana Harvard Health Partnership (BHP), through its Clinical Capacity Building Global Health Program in partnership with Beth Israel Deaconess Medical Center (BIDMC) and Oregon Health & Science University (OHSU), successfully delivered essential healthcare services to remote communities through a large-scale outreach initiative in Sepako village.

Located approximately 850 kilometres from Gaborone, the outreach extended services beyond Sepako to surrounding communities, including Nata, Maposa, and Manxotae, significantly improving access to care in underserved areas.

The outreach is part of a broader community health campaign led by BHP in collaboration with a coalition of partners and stakeholders. The initiative aims to address the social determinants of health that disproportionately affect vulnerable populations, particularly women in remote communities, by bringing essential healthcare services closer to where they are most needed.

“With cervical cancer remaining one of the leading causes of cancer-related deaths in Botswana, the campaign placed strong emphasis on prevention and

early detection. More than 230 clients were reached during the outreach, receiving cervical cancer screening through VIA (Visual Inspection with Acetic Acid) and Pap smears, alongside breast cancer screening,” said Dr Kesegofetse Chabaesele, BHP Clinical Capacity Building Global Health Program Site Director.

Dr Chabaesele added that community members benefited from general health screenings, including blood pressure, diabetes, and HIV testing. She further noted that doctors conducted general medical consultations to address a wide range of health concerns, ensuring a holistic approach to care.

To enhance diagnostic capacity, the team deployed point-of-care technologies, including ultrasound and ECG machines, improving the quality and accuracy of primary healthcare services delivered in the field.

The outreach also involved a multidisciplinary clinical team comprising a global health fellow and residents from internal medicine, family medicine, obstetrics and gynaecology, and general surgery, providing both service delivery and hands-on training. Laboratory staff were also part of the outreach, ensuring that samples were processed and analyzed on-site, significantly

reducing the usual testing turnaround time.

The official opening of the outreach was conducted by the area Member of Parliament and Assistant Minister of Health, Lawrence Ookeditse, who commended the collaborative effort for improving access to critical health services in rural communities.

This outreach by BHP and its partners aligns with the broader goal of advancing universal health coverage by improving accessibility, strengthening early detection of diseases, and enhancing the quality of primary healthcare. Participation in this initiative reaffirmed BHP's commitment to continued collaboration and innovation in delivering impactful health interventions that improve livelihoods across Botswana.

The programme was supported by site directors Dr Kesegofetse Chabaesele, Dr Catriona Stewart, and Dr Sally Hanson, alongside former site directors Dr Rebecca Luckett and Dr Sara Schwanke Khilji, reflecting strong institutional support and continuity.



Member of Parliament for Nata-Gweta and Assistant Minister of Health, Lawrence Ookeditse.

Phodiso and Tsepamo Teams Trained on Study Protocols and Compliance

The Phodiso and Tsepamo study teams recently underwent targeted training sessions to strengthen their understanding of study protocols and facilitate adherence to research and institutional procedures. These sessions are part of BHP's ongoing commitment to research excellence, regulatory compliance, and effective community engagement, ensuring teams are equipped to conduct studies with accuracy, integrity, and clarity.

The Phodiso study, an HIV cure research initiative that seeks to understand why HIV persists in the body despite successful antiretroviral therapy (ART), particularly among adolescents on long-term ART, held a refresher training on 09 March 2026 to review protocol amendments. Led by the study's Principal Investigator, Prof Catherine Koofhethile, the session guided the team through updated study procedures, ensuring compliance with approved changes and reinforcing best practices in research implementation.

The Tsepamo study, which monitors the health of newborn babies in hospitals across Botswana, tracking birth outcomes and any birth defects, held a week-long training from 16–22 March 2026 on the new

Tsepamo NexGen study, an extension of the ongoing research. The training ensured that team members fully understood the study protocol, standard operating procedures (SOPs), and their individual and collective responsibilities, preparing them to conduct research efficiently and accurately. The session was led by the Study Coordinator, Modiegi Diseko.

Support services departments provided the Tsepamo team with refresher compliance training, covering key policies and procedures from Finance, Grants, Human Resources, Procurement, Information Technology, and Communications. Each department outlined its core functions and essential procedures critical to smooth study operations. Similar sessions are scheduled for the remaining study teams in April 2026.

The Communications Office, in collaboration with the Regulatory and Community & Stakeholder Engagement teams, conducted a session on using plain language in health research. This training emphasized how to communicate complex scientific concepts in everyday language, helping study teams improve understanding and uptake of research findings among stakeholders and community members.

BHP Participates in World TB Day Commemorations



BSRHI and Community & Stakeholder Engagement team at Tlokweg.

Botswana Harvard Health Partnership (BHP) actively participated in the World Tuberculosis (TB) Day commemorations held in Mogoditshane and Tlokweg on 24 March 2026, hosted by the Mogoditshane-Thamaga District Council and Tlokweg District Council, respectively. The events highlighted ongoing efforts to raise awareness about TB prevention, treatment, and research in local communities.

BHP collaborates closely with these councils, which now house primary healthcare services following the transition of certain health functions from the Ministry of Health. Through this partnership, BHP engages with various local clinics, recruiting potential study participants and receiving referrals for enrollment in its ongoing research studies.

At both events, BHP set up exhibition stalls to showcase its research programs and community health initiatives. In Mogoditshane, the BHP Clinical Trials Unit (CTU) ACTG team, which conducts TB studies, presented their work alongside the Communications team. Meanwhile, in Tlokweg, a team from the Botswana Sexual Reproductive Health Initiative (BSRHI) at BHP, accompanied by the Community and Stakeholder Engagement Coordinator, showcased ongoing research and community programs.

In support of the councils and attendees, BHP also

donated bottled water for use during the events, underscoring its commitment to community engagement and well-being.

Through its participation, BHP reinforced its mission of advancing health research, strengthening community partnerships, and improving access to care and information for populations affected by TB and other health challenges.



Ernest Moseki engaging with members of the community at the BHP stall in Tlokweg.



CTU Research Nurse Shamillah Tshuma, engaging with members of the community at the BHP stall in Mogoditshane.



Members of the community attending World TB Day Commemoration in Mogoditshane.

BHP Bids Farewell to Long-Serving Security Officer Mr Kenosi Ntsima



Administration and Lab staff posing for a photo with Mr Kenosi Ntsima.

The Botswana Harvard Health Partnership (BHP), on 1 April 2026, bid a heartfelt farewell to its long-serving Security Officer, Mr Kenosi Ntsima, who retires after years of dedicated service, having joined the organisation in 2003.

Mr Ntsima's journey with BHP began when he was employed by a private security company contracted to the institution. His professionalism, discipline, and commitment quickly set him apart, earning him direct employment with BHP, an opportunity that reflected the high regard in which he was held.

During a small but warm send-off ceremony attended by staff from Administration and the Laboratory, Mr Ntsima was celebrated as a steadfast and respected professional. Colleagues described him as punctual, dependable, and deeply committed to his duties, qualities that made him a trusted presence within the organisation.

Fondly known as "Malome," Mr Ntsima was also recognised for his strong faith. He carried his Bible to work daily, which he regarded as his source of strength and protection, guiding him in the execution of his responsibilities.

Laboratory staff, particularly those working night shifts, shared heartfelt reflections on the sense of safety and reassurance he provided. They noted that his presence allowed them to work peacefully through the night, knowing they were in the care of a vigilant and reliable colleague.

In appreciation of his years of service, Mr Ntsima was presented with gifts including a TrimTech petrol chainsaw, a jerrycan, and a 5-litre adjustable pressure sprayer for home and garden use.

In his farewell remarks, Mr Ntsima expressed gratitude to BHP for the opportunity to serve and for the support he received over the years. He paid special tribute to his supervisor, Ms Bernadette Kgakge, whom he credited for recognising his dedication early on and ensuring he remained with BHP.

Mr Ntsima now retires to his home village of Moshupa, leaving behind a legacy of professionalism, faith, and unwavering commitment.



Mr. Kenosi Ntsima

Publications

[Tuberculosis preventive therapy in postpartum women with HIV modifies M. tuberculosis-specific and nonspecific immune responses.](#) Yengkhom D, Montepiedra G, Masheto G, Wabwire D, Stranix-Chibanda L, Matubu A, Violari A, Theron G, Gupta A, Weinberg A. *Front Immunol.* 2026 Mar 11;17:1722621. doi: 10.3389/fimmu.2026.1722621. eCollection 2026. PMID: 41890718 Free PMC article.

[Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial.](#) Murphy K, Nel JS, Moosa MY, Wilson DP, Tsitsi M, Mfinanga S, Kivuyo S, Kyazze D, Alam N, Meintjes G, Eriksson M, Adams J, Menezes C, Variava E, Black J, Bremer M, Dat VQ, Le T, Schutz C, Loyse A, Wake RM, Lawrence DS, Wang D, Jaffar S, Jarvis JN, Harrison TS, Molloy SF, Govender NP. *Trials.* 2026 Mar 24. doi: 10.1186/s13063-026-09520-x. Online ahead of print. PMID: 41877274 Free article.

[Healthcare Providers' Perceptions and Experiences of Prenatal Iron and Folic Acid Supplementation-A Qualitative Study in Botswana.](#) Moeng L, Kebaabetswe P, Diseko M, Zash R, Mayondi G, Mabuta J, Mmalane M, Makhema J, Lockman S, Lowenthal E, Shapiro R, Caniglia EC. *Curr Dev Nutr.* 2026 Feb 25;10(3):107660. doi: 10.1016/j.cdnut.2026.107660. eCollection 2026 Mar. PMID: 41847266 Free PMC article.

[Unpacking sources of transmission in HIV prevention trials with deep-sequence pathogen data.](#) Magosi LE, Tchetgen ET, Novitsky V, Pretorius Holme M, Moore J, Bachanas P, Lebelonyane R, Fraser C, Moyo S, Hurwitz KE, Gaolathe T, Goyal R, Makhema J, Lockman S, Essex M, De Gruttola V, Lipsitch M. *Nat Commun.* 2026 Mar 14. doi: 10.1038/s41467-026-70203-x. Online ahead of print. PMID: 41832151 Free article.

[Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study.](#) Martin MA, Blenkinsop A, Moffa M, Reynolds SJ, Nalugoda F, Quinn TC, Kigozi G, Ssekubugu R, Gupta RK, Grayson NE, MacIntyre-Cockett G, Kagaayi J, Nakigozi G, Abeler-Dörner L, Fraser C, Ratmann O, Tobian AAR, Laeyendecker O, Moyo S, Kennedy CE, Bonsall D, Galiwango RM, Grabowski MK. *Clin Infect Dis.* 2026 Mar 13:ciag161. doi: 10.1093/cid/ciag161. Online ahead of print. PMID: 41819144

[Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis \(IMPROVE\): a non-inferiority, randomised controlled trial.](#) Ellis J, Hale G, Nsangi LJ, Wele A, Kigozi E, Gakuru J, Kagimu E, Mugabi T, Namombwe S, Kimuda S, Ssekindi F, Ndyetukira JF, Sadiq A, Tukundane A, Bakka W, Harrison TS, Mande E, Muzooro C, Moore DAJ, Meya DB, Fielding K, Boulware DR, Jarvis JN. *Lancet HIV.* 2026 Mar;13(3):e153-e162. doi: 10.1016/S2352-3018(25)00246-2. Epub 2026 Feb 6. PMID: 41662846 Free article. Clinical Trial.

[Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED.](#) Nguyen T, Chae JW, Ziembra L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD; IMPAACT 2010/VESTED Protocol Team. *J Acquir Immune Defic Syndr.* 2026 Mar 1;101(3):296-301. doi: 10.1097/QAI.0000000000003796. PMID: 41195894 Free PMC article.

[Pre-Eclampsia Rates in Women With and Without HIV in Modern ART Era in Botswana.](#) Wamakima B, Diouf K, Modest A, Macharia A, Boikanyo K, Hanson SJ, Diseko M, Mabuta J, Rubgega F, Morroni C, Caniglia E, Jackson-Gibson M, Makhema J, Hofmeyr J, Zash R, Shapiro R, Luckett R. *J Acquir Immune Defic Syndr.* 2026 Mar 1;101(3):241-248. doi: 10.1097/QAI.0000000000003791. PMID: 41195806

[Reducing HIV incidence and mortality: two sides of the same coin in the approach to ending AIDS.](#) Jarvis JN, Ehrenkrantz P, Lawrence DS, Keene CM, Reid MJ, Katz IT, Shodell D, Pérez-Casas C, Mupeli K, Sivile S, Couto AM, Doherty M, Rangaraj A, Ford N. *Lancet HIV.* 2026 Mar;13(3):e207-e212. doi: 10.1016/S2352-3018(25)00265-6. Epub 2025 Oct 21. PMID: 41135558 Review.

[Pubertal onset in children with in-utero HIV/antiretroviral exposure in Botswana.](#) Jao J, Gochanour C, Williams PL, Schenkel S, Kgole S, Masasa G, Phale B, Kgathi C, Makhema J, Ralegoreng T, Masheto G, Shaw ND, Serghides L, Shapiro R, Lockman S, Powis KM. *AIDS.* 2026 Mar 1;40(3):336-342. doi: 10.1097/QAD.0000000000004374. Epub 2025 Oct 6. PMID: 41055964

[Self-reported sleep quality and frailty in middle-aged people living with HIV in an African setting: a pilot study.](#) Zheng X, Cai R, Gao C, Ponatshego P, Gao L, A Montano M, Hu K, Mosepele M, Li P. *AIDS Care.* 2026 Mar;38(3):650-660. doi: 10.1080/09540121.2025.2564882. Epub 2025 Oct 6. PMID: 41051019 Free PMC article.

VISION

To Be a World-Renowned Public Health Institute.

MISSION

To Fight HIV/AIDS and Emerging Public Health Challenges Through Innovative Research, Education, and Capacity Building That Impacts Policy and Practice.

CORE VALUES

BENEFICENCE

INNOVATION

COLLABORATION

EXCELLENCE

BOTHO

Botswana Harvard Health Partnership
Private Bag BO320 Gaborone
Plot No. 1836, Northring Road, Princess
Marina Hospital, Gaborone
Tel: +267 3902671, Fax: +267 3901284
Web: www.bhp.org.bw

